Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease

Edwin M. Spithoven, Anneke Kramer, Esther Meijer, Bjarne Orskov, Christoph Wanner, Fergus Caskey, Frederic Collart, Patrik Finne, Damian G. Fogarty, Jaap W. Groothoff, Andries Hoitsma, Marie-Beatrice Nogier, Maurizio Postorino, Pietro Ravani, Oscar Zurriaga, Kitty J. Jager, Ron T. Gansevoort*, ERA-EDTA Registry, EuroCYST Consortium, WGIKD

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

62 Citaten (Scopus)

Samenvatting

Autosomal dominant polycystic kidney disease (ADPKD) is a major cause of end-stage kidney failure, but is often identified early and therefore amenable to timely treatment. Interventions known to postpone the need for renal replacement therapy (RRT) in non-ADPKD patients have also been tested in ADPKD patients, but with inconclusive results. To help resolve this we determined changes in RRT incidence rates as an indicator for increasing effective renoprotection over time in ADPKD. We analyzed data from the European Renal Association-European Dialyses and Transplant Association Registry on 315,444 patients starting RRT in 12 European countries between 1991 and 2010, grouped into four 5-year periods. Of them, 20,596 were due to ADPKD. Between the first and last period the mean age at onset of RRT increased from 56.6 to 58.0 years. The age-and gender-adjusted incidence rate of RRT for ADPKD increased slightly over the four periods from 7.6 to 8.3 per million population. No change over time was found in the incidence of RRT for ADPKD up to age 50, whereas in recent time periods the incidence in patients above the age of 70 clearly increased. Among countries there was a significant positive association between RRT take-on rates for non-ADPKD kidney disease and ADPKD. Thus, the increased age at onset of RRT is most likely due to an increased access for elderly ADPKD patients or lower competing risk prior to the start of RRT rather than the consequence of effective emerging renoprotective treatments for ADPKD.

Originele taal-2English
Pagina's (van-tot)1244-1252
Aantal pagina's9
TijdschriftKidney International
Volume86
Nummer van het tijdschrift6
DOI's
StatusPublished - dec-2014

Citeer dit